Skip to main content Skip to main navigation menu Skip to site footer

Assessing keloid treatment efficacy: a comparison of intralesional umbilical-cord mesenchymal stem cells, their conditioned medium, and triamcinolone acetonide injection through macroscopic and microscopic examination

  • Anastasia Dessy Harsono ,
  • Ismail Hadisoebroto Dilogo ,
  • Theddeus Octavianus Hari Prasetyono ,
  • Marcel Prasetyo ,
  • Retno Asti Werdhani ,
  • Sri Widia Jusman ,
  • Nuryati Chairani Siregar ,
  • Hardisiswo Soedjana ,


Link Video Abstract:


Background: Current keloid treatment involves intralesional injection of triamcinolone acetonide (TA), which, despite its usage, is associated with high recurrence rates and adverse effects. Mesenchymal stem cells (MSCs) exhibit potent proliferative abilities and can curb fibroblast activity and proliferation within keloids. It is now known that umbilical cord mesenchymal stem cells (UC-MSCs) have been shown to have greater proliferative potential than bone marrow-derived MSCs (BM-MSCs), and other advantages of UC-MSCs include being easily accessible and less immunogenic. To assess the viability of administering umbilical cord MSC (UC-MSC) and its conditioned medium (UC-CM) via intralesional injection compared to TA in reducing macroscopic keloid volume and type 1:3 collagen ratio.

Methods: This randomized controlled trial enrolled twenty-four keloid patients by consecutive sampling. Eligible patients were required to have keloids on the chest, back, abdomen, or extremities. Patients with hypertrophic scars, a history of kidney failure, hypertension, blood disorders, malignancy, pregnancy, breastfeeding, or keloid treatment were excluded. Sociodemographic data, keloid size, and tissue biopsies were collected during scheduled visits. Bivariate analyses applied were considered significant at a p-value of <0.05.

Results: The study revealed that the most significant decrease in macroscopic volume occurred within the UC-MSC group, followed by the UC-CM group, and then the TA group (UC-MSC: 50.24% ± 3.58%; UC-CM: 43.97% ± 3.04%; TA: 33.53% ± 2.64; p = 0.004. The UC-CM group exhibited the most substantial decrease in the type 1:3 collagen ratios (4.80±0.26), with UC-MSC (4.60(4.15-8.05)) and TA (3.96(1.63-4.14)) following in sequence (p=0.002).

Conclusion: The findings of this study indicate that the use of UC-MSC and UC-CM exhibits promising superiority over TA in terms of reducing macroscopic keloid volume and type 1:3 collagen ratio.


  1. Lee YI, Kim J, Yang CE, Hong JW, Lee WJ, Lee JH. Combined Therapeutic Strategies for Keloid Treatment. Dermatologic Surgery. 2019;45(6):802–10. Available from:
  2. Jaloux C, Bertrand B, Degardin N, Casanova D, Kerfant N, Philandrianos C. Les cicatrices chéloïdes (deuxième partie) : arsenal et stratégie thérapeutique. Annales de Chirurgie Plastique Esthétique. 2017;62(1):87–96. Available from:
  3. Berman B, Maderal A, Raphael B. Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment. Dermatologic Surgery. 2017;43(1):S3–18. Available from:
  4. Oei F, Putra IB, Jusuf NK. The relationship between skin color and keloid. Bali Medical Journal. 2021;10(2):835–8.
  5. Trisliana Perdanasari A, Lazzeri D, Su W, Xi W, Zheng Z, Ke L, et al. Recent developments in the use of intralesional injections keloid treatment. Arch Plast Surg. 2014/11/03. 2014;41(6):620–9. Available from:
  6. Viera MH, Vivas AC, Berman B. Update on Keloid Management: Clinical and Basic Science Advances. Adv Wound Care (New Rochelle). 2012;1(5):200–6. Available from:
  7. Huang C, Liu L, You Z, Du Y, Ogawa R. Managing keloid scars: From radiation therapy to actual and potential drug deliveries. Int Wound J. 2019/03/12. 2019;16(3):852–9. Available from:
  8. Jones ME, McLane J, Adenegan R, Lee J, Ganzer CA. Advancing Keloid Treatment: A Novel Multimodal Approach to Ear Keloids. Dermatologic Surgery. 2017;43(9):1164–9. Available from:
  9. Cotellese R, Hu S, Belcaro G, Ledda A, Feragalli B, Dugall M, et al. Centella asiatica (Centellicum®) facilitates the regular healing of surgical scars in subjects at high risk of keloids. Minerva Surgery. 2018;73(2). Available from:
  10. Lim KH, Itinteang T, Davis PF, Tan ST. Stem Cells in Keloid Lesions: A Review. Plast Reconstr Surg Glob Open. 2019;7(5):e2228–e2228. Available from:
  11. Sato C, Yamamoto Y, Funayama E, Furukawa H, Oyama A, Murao N, et al. Conditioned Medium Obtained from Amnion-Derived Mesenchymal Stem Cell Culture Prevents Activation of Keloid Fibroblasts. Plastic & Reconstructive Surgery. 2018;141(2):390–8. Available from:
  12. Haly Q, Sartika CR, Haifa R, Karina N, Rahmawati V, Naura NF. Combination treatment of Umbilical Cord-derived Mesenchymal Stem Cell (UC-MSC) and Umbilical Cord Mesenchymal Stem Cell-derived Conditioned Medium (UCMSC-CM) for Keloid Post Chronic Burn Injury: A Case Report. Vol. 18, Malaysian Journal of Medicine and Health Sciences. 2022.
  13. Fan D, Zeng M, Xia Q, Wu S, Ye S, Rao J, et al. Efficacy and safety of umbilical cord mesenchymal stem cells in treatment of cesarean section skin scars: a randomized clinical trial. Stem Cell Res Ther. 2020;11(1):244.
  14. Sumorejo P, Listiawan MY, Putri AI, Rantam FA, Susilowati H, Hendrianto E. The role of stem cell metabolites derived from placenta for skin regeneration: An in vitro study. Bali Medical Journal. 2019;8(1):354–9.
  15. Harahap DH, Irdam GA. Human umbilical cords mesenchymal stem cells for kidney diseases. Vol. 11, Bali Medical Journal. Sanglah General Hospital; 2022. p. 155–9.
  16. Ataş ÖK, Altunay SA, Karada÷ Ö, Aktaú S. Optimal Sample Size Determination for the ANOVA Designs STUDENTS’ OPINIONS ABOUT SCIENCE AND TECHNOLOGY IN TURKEY AND THE UNITED STATES: A CROSS-CULTURAL STUDY View project Beta Regression View project Optimal Sample Size Determination for the ANOVA Designs [Internet]. 2011. Available from:
  17. Pawitan JA, Goei N, Liem IK, Mediana D. Effect of Cryopreservation and cumulative population doublings on Senescence of Umbilical Cord Mesenchymal Stem Cells. Int J Pharmtech Res. 2017;10(2):109–13. Available from:
  18. Arjunan S, Gan SU, Choolani M, Raj V, Lim J, Biswas A, et al. Inhibition of growth of Asian keloid cells with human umbilical cord Wharton’s jelly stem cell-conditioned medium. Stem Cell Res Ther. 2020;11(1):78. Available from:
  19. Liu J, Ren J, Su L, Cheng S, Zhou J, Ye X, et al. Human adipose tissue-derived stem cells inhibit the activity of keloid fibroblasts and fibrosis in a keloid model by paracrine signaling. Burns. 2018;44(2):370–85. Available from:
  20. Harsono AD, Prasetyono TOH, Dilogo IH. The Role of Interleukin 10 in Keloid Therapy. Ann Plast Surg. 2021;88(6):617–21. Available from:
  21. Huang C, Murphy GF, Akaishi S, Ogawa R. Keloids and hypertrophic scars: update and future directions. Plast Reconstr Surg Glob Open. 2013;1(4):e25–e25. Available from:
  22. Chen J, Li Z, Huang Z, Liang L, Chen M. Chyle Fat–Derived Stem Cells Conditioned Medium Inhibits Hypertrophic Scar Fibroblast Activity. Ann Plast Surg. 2019;83(3):271–7. Available from:
  23. Liu Y-X, Sun J-M, Ho C-K, Gao Y, Wen D-S, Liu Y-D, et al. Advancements in adipose-derived stem cell therapy for skin fibrosis. World J Stem Cells. 2023;15(5):342–53. Available from:

How to Cite

Harsono, A. D., Dilogo, I. H. ., Prasetyono, T. O. H. ., Prasetyo, M. ., Werdhani, R. A. ., Jusman, S. W. ., Siregar, N. C. ., & Soedjana, H. . (2023). Assessing keloid treatment efficacy: a comparison of intralesional umbilical-cord mesenchymal stem cells, their conditioned medium, and triamcinolone acetonide injection through macroscopic and microscopic examination. Bali Medical Journal, 12(3), 2668–2673.




Search Panel

Anastasia Dessy Harsono
Google Scholar
BMJ Journal

Ismail Hadisoebroto Dilogo
Google Scholar
BMJ Journal

Theddeus Octavianus Hari Prasetyono
Google Scholar
BMJ Journal

Marcel Prasetyo
Google Scholar
BMJ Journal

Retno Asti Werdhani
Google Scholar
BMJ Journal

Sri Widia Jusman
Google Scholar
BMJ Journal

Nuryati Chairani Siregar
Google Scholar
BMJ Journal

Hardisiswo Soedjana
Google Scholar
BMJ Journal